Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
Edit Your Profile
Novel radiosensitizers for tumors of the central nervous system
Article
Mehta, MP, Suh, JH. (2004). Novel radiosensitizers for tumors of the central nervous system .
5(12), 1284-1291.
Share this citation
Twitter
Email
Mehta, MP, Suh, JH. (2004). Novel radiosensitizers for tumors of the central nervous system .
5(12), 1284-1291.
Copy Citation
Share
Overview
Additional Document Info
View All
Overview
cited authors
Mehta, MP; Suh, JH
authors
Mehta, Minesh
abstract
Radiotherapy is widely used in the management of tumors of the central nervous system (CNS) primarily because these tumors, in general, remain localized and are usually not completely removed at surgery. Therefore, radiotherapy serves as a valuable adjunct. However, due to radiation resistance, survival for most patients with CNS tumors remains poor. Radiosensitizers are considered useful for CNS tumors because the majority of these tumors cause death due to local progression, thus emphasizing the significance of improving local control. In addition, these neoplasms consist of a rapidly growing cell population surrounded by slowly proliferating normal brain cells, thereby affording an opportunity for tumor-selectivity. Historically, several classes of radiation sensitizers, including S-phase halogenated pyrimidines, oxygen mimetics and others, have been tested without clear evidence of clinical benefit. Recently, two agents with very different mechanisms of action have gained attention and are currently in clinical trials; these agents, efaproxiral, a modulator of tumor hypoxia, and motexafin-gadolinium, a redox modulator, are the focus of this review. © The Thomson Corporation.
publication date
December 1, 2004
Additional Document Info
start page
1284
end page
1291
volume
5
issue
12